Nørgaard JN, Moore KLF, Slørdahl TS, Vik A, Tvedt THA, Monsen HB, Schjesvold F (2026)
High-dose melphalan and autologous haematopoietic stem cell transplantation in multiple myeloma in Norway, 2008-2020
Tidsskr Nor Laegeforen, 146 (5)
DOI 10.4045/tidsskr.25.0498, PubMed 42012109

Gay F, Roeloffzen W, Dimopoulos MA, Rosiñol L, van der Klift M, Mina R, Oriol A, Katodritou E, Wu KL, Rodríguez Otero P, Hájek R, Antonioli E, van Duin M, D'Agostino M, Martínez-López J, van Leeuwen-Segarceanu EM, Zamagni E, van de Donk NWCJ, Weisel KC, Pour L, Radocha J, Belotti A, Schjesvold F, Bladé J, Einsele H et al. (2026)
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial
Nat Med (in press)
DOI 10.1038/s41591-026-04282-0, PubMed 41942646

Schjesvold F, Spencer A, Cohen YC, Ocio EM, Lopez-Pardo J, Cafro AM, Callander NS, Kaufman JL, Mohan M, Wermke M, Doki N, Kan R, Milanez-Almeida P, Stein A, Trabucco G, Ye S, Kulec K, Sechaud R, Banerjee S, Zhong H, Lai C, Rauch PJ, Raab MS (2026)
Final clinical data of a phase 1 dose-escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ-secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma
Cancer, 132 (7), e70341
DOI 10.1002/cncr.70341, PubMed 41880322